PL7 New Signaling Pathways and Novel Approaches for Treating Metabolic Bone Disease

Program: Plenary
Translational Session
Monday, April 4, 2016: 8:45 AM-9:45 AM
Grand Ballroom East (BCEC)

Hormone action, PTH and vitamin D:  From three Nobels to multiple new calcium hormones, new mechanisms and novel therapies for bone disease.

8:45 AM
Lisa H Fish, MD, Hennepin County Medical Ctr, Edina, MN
Nothing to Disclose: LHF
8:55 AM
Laurie Kay McCauley, DDS, PhD, University of Michigan School of Dentistry, Ann Arbor, MI
Nothing to Disclose: LKM
9:20 AM
Michael R McClung, MD, FACP, Oregon Osteoporosis Center, Portland, OR
Disclosures:
MRM: Consultant, Amgen, Consultant, Eli Lilly & Company, Speaker, GlaxoSmithKline, Consultant, Merck & Co..
See more of: Plenary

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire